SELECTION Positive For Gilead/Galapagos’s Filgotinib In UC But Will It Be Enough To Compete?
Ulcerative Colitis Market Is Crowded
Executive Summary
Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.